The serum levels somatostatin in type 2 diabetes mellitus

The dynamic study of somatostatin secretion was performed in 105 patients, with noninsulin dependent diabetes mellitus and 40 healthy volounteers. The patients were divided into groups in relation to the presence of autonomic neuropathy and metabolic control of diabetes mellitus. Serum somatostatin secretion was determined employeing a specific RIA method. An oral administration of a protein rich meal was performed in all subjects. The serum levels of somatostatin were not significantly different between type 2 diabetics and controls. There were no significant difference between the group with and the group without autonomic neuropathy. Diabetics in poor metabolic control had significantly increased in somatostatin (54.0 ± 22.2 pmol/L) levels compared with group well compensated (48.8 ± 16.5 pmol/L) (p < 0.01). Data of increased somatostatin levels in poor controlled diabetics suggest it-s pathophysiological role in type 2 diabetes mellitus.

[1]  B. Boehm,et al.  Use of somatostatin receptor ligands in obesity and diabetic complications. , 2002, Best practice & research. Clinical gastroenterology.

[2]  Hyoung-Jin Park,et al.  Endogenous Somatostatin Inhibits Interaction of Insulin and Cholecystokinin on Exocrine Secretion of Isolated, Perfused Rat Pancreas , 2002, Pancreas.

[3]  H. Grønbaek,et al.  Inhibitory effects of octreotide on renal and glomerular growth in early experimental diabetes in mice. , 2002, The Journal of endocrinology.

[4]  A. Flyvbjerg,et al.  Effects of the somatostatin analogue octreotide on renal function in conscious diabetic rats. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  E. Ortega,et al.  Decreased Insulin Requirements After LAR-Octreotide but not After Lanreotide in an Acromegalic Patient , 2001, Pituitary.

[6]  Busiguina,et al.  Anatomically Specific Changes in the Expression of Somatostatin, Growth Hormone‐Releasing Hormone and Growth Hormone Receptor mRNA in Diabetic Rats , 2000, Journal of neuroendocrinology.

[7]  K. Huh,et al.  Effects of long-acting somatostatin analogue (Sandostatin) on manifest diabetic ketoacidosis. , 1999, Journal of diabetes and its complications.

[8]  M. El-Salhy.  Neuroendocrine peptides in stomach and colon of an animal model for human diabetes type I. , 1999, Journal of diabetes and its complications.

[9]  J. Salvador,et al.  Effects of cholinergic blockade on nocturnal thyrotropin and growth hormone (GH) secretion in type I diabetes mellitus: further evidence supporting somatostatin's involvement in GH suppression. , 1997, Metabolism: clinical and experimental.

[10]  M. Grant,et al.  Somatostatin analogues as drug therapies for retinopathies. , 2002, Drugs of today.

[11]  I. Lancranjan,et al.  Effect of octreotide, captopril or insulin on renal changes and UAE in long-term experimental diabetes. , 1998, Kidney international.